WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced it has been honored for employee development and business process programs delivering service excellence for biopharmaceutical clients.
Training magazine named the company for the sixth consecutive year to its Top 125 list of businesses that excel in employee learning and development. For the second year, PPD placed in the Process Excellence Network (PEX) Awards, which recognize best practices in business processes.
“PPD integrates technology, process improvement and training into our client service model to foster a business culture of continuous improvement,” said Mike Wilkinson, executive vice president and chief information officer for PPD. “We are focused on a relentless pursuit of productivity improvement to help our clients reduce the time and cost of drug development.”
The PEX Network Awards feature companies that improve quality and efficiency by using process methodologies and managing strategic goals and change. PPD placed in two categories: Best Business Process Improvement Program over Two Years for its rollout of Lean Six Sigma, and Best Business Transformation Project for its virtual investigator meeting program. The program uses a web-based interface to help prepare study investigators to successfully deliver clinical trials. PPD accepted its PEX Network Awards at the OPEX Week USA 2017 event in Orlando.
“Through PPD’s strong OPEX programs and innovative approaches, and the engagement and dedication of their OPEX teams, they made a big impact on the judges,” said Karen Magnusson, divisional director, PEX Network.
The Training Top 125 list honors companies that demonstrate measurable results from effective employee learning and development, tied to strategic goals. PPD retained a ranking in the Top 50 and accepted the award during the Training 2017 Conference & Expo in San Diego.
“Learning and development at PPD engages our employees and offers our clients a highly skilled workforce to rely on,” said Ed Murray, executive vice president and chief human resource officer for PPD. “We are dedicated to providing our clients superior performance in helping bring new medicines to patients.”
PPD employee learning and development initiatives span leadership and employee development and training, which are integrated and aligned with business goals and objectives. PPD’s global training governance board, an enterprise-wide, cross-functional group of leaders, works to ensure that PPD is an efficient, high-performing organization that provides its employees with necessary and appropriate learning and development opportunities. PPD designs, develops and deploys a range of learning and performance programs to meet the specific needs of biopharmaceutical clients in advancing their clinical research programs.
“PPD did a stellar job of proving its training effectiveness with concrete results that helped achieve corporate strategic goals,” said Lorri Freifeld, editor-in-chief of Training magazine. “It demonstrated an organization-wide commitment to and passion for employee training and development that resulted in high levels of employee engagement and performance."
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and more than 18,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s award-winning learning, development and process excellence programs, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward- looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; rapid technological advances that make our services or capabilities less competitive; compliance with drug development regulations; changes in the regulation of the drug development process; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher- than-expected cancellation rates; the rate of conversion of backlog into revenue; risks associated with and dependence on strategic relationships; actual operating performance; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.